Background: The prevalence of restless legs syndrome (RLS) among the general population is 2–15%, and with fibromyalgia syndrome (FMS) 2%. Both RLS and FMS are more common among women. The aim of our study was to evaluate the prevalence of RLS in a group of female patients diagnosed with FMS and to compare the occurrence of symptoms of daytime sleepiness and experienced sleep disorders between fibromyalgia patients with or without RLS. Method: Three hundred and thirty-two female patients, 20–60 years old, diagnosed with FMS at Skönviks Rehab between 2002 and 2006, answered a questionnaire mailed to their home address. The questionnaire consisted of the international RLS study group criteria as well as of questions concerning symptoms of insomnia and daytime sleepiness measured according to the Epworth Sleepiness Scale. Results: Nearly 64% of the women were also suffering from RLS. More patients suffering from both RLS and FMS were affected by problems of initiating and maintaining sleep than those suffering from FMS only. More patients suffering from both RLS and FMS did not feel refreshed on awakening compared with those suffering from FMS without RLS. The patients with concomitant RLS and FMS were more often hypersomnolent than those suffering from FMS only. Conclusion: This study shows that 64% of a group of female patients diagnosed with fibromyalgia also concurrently suffered from RLS. Compared with patients who suffer from FMS only, patients with both FMS and RLS more often experience sleep disturbances and pronounced daytime sleepiness.

Mease P: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005;75:6–21.
Clauw DJ: Fibromyalgia: update on mechanisms and management. Clin Rheumatol 2007;13:102–109.
Shaver JL: Fibromyalgia syndrome in women. Nurs Clin North Am 2004;39:195–204.
Millea PJ, Holloway RL: Treating fibromyalgia. Am Fam Physician 2000;62:1575–1582, 1587.
Ekbom KA: Restless legs. Acta Med Scand 1945;158(suppl):1–123.
Trenkwalder C, Paulus W, Walters AS: The restless legs syndrome. Lancet Neurol 2005;4:465–475.
Rothdach AJ, Trenkwalder C, Haberstock J, et al: Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 2000;54:1064–1068.
Ulfberg J, Nyström B, Carter N, Edling C: Restless legs syndrome among working-aged women. Eur Neurol 2001;46:17–19.
Ohayon MM, Roth T: Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547–554.
Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A: Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005;65:239–246.
Bjorvatn B, Leissner L, Ulfberg J, Gyring J, Karlsborg M, Regeur L, Skeidsvoll H, Nordhus IH, Pallesen S: Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med 2005;6:307–312.
Desautels A, Turecki G, Montplaisir J, Ftouhi-Paguin N, Michaud M, Chouinard VA, Rouleau GA: Dopaminergic neurotransmission and restless legs syndrome: a genetic association analysis. Neurology 2001;57:1304–1306.
Kemlink D, Plazzi G, Vetrugno R, Provini F, Polo O, Stiasny-Kolster K, Oertel W, Nevsimalova S, Sonka K, Högl B, Frauscher B, Hadjigeorgiou GM, Pramstaller PP, Lichtner P, Meitinger T, Muller-Myshok B, Winkelmann J, Montagna P: Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics 2008;9:75–82.
Allen RP, Earley CJ: Restless legs syndrome; a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001;18:128–147.
Gosselin N, Lanfranchi P, Michaud M, Fantini L, Carrier J, Lavigne G, Montplaisir J: Age and gender effects on heart rate activation associated with periodic leg movements in patients with restless legs syndrome. Clin Neurophysiol 2003;114:2188–2195.
Yunus MB, Aldag JC: Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996;312:1339.
Shaver JLF, Wilbur J, Robinson FP, Wang E, Buntin MS: Women’s health issues with fibromyalgia syndrome. J Womens Health 2006;15:1035–1045.
Walters AS: Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634–642.
Allen RP, Picchietti D, Hening WA, et al: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101–119.
Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C, de Weerd A: Pathophysiological concepts of restless legs syndrome. Mov Disord 2007;22:1451–1456.
Johns MW: A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 1991;14:540–545.
Wood PB: Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med Hypotheses 2004;62:420–424.
Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, Bushnell MC, Chizh BA: Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007;25:3576–3582.
Holman AJ, Myers RR: A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495–2505.
Arnold LM: Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006;8:212.
Crofford LJ: Pain management in fibromyalgia. Curr Opin Rheumatol 2008;20:246–250.
Späth M, Stratz T, Neeck G, Kötter I, Hammel B, Amberger CC, Haus U, Färber L, Pongratz D, Muller W: Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004;33:267–270.
Stiasny-Kolster K, Möller JC, Zschocke J, Bandmann O, Cassel W, Oertel WH, Hoffmann GF: Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov Disord 2004;19:192–196.
Buskila D, Neumann L: Genetics of fibromyalgia. Curr Pain Headache Rep 2005;9:313–315.
Frank B, Niesler B, Bondy B, Späth M, Pongratz DE, Ackenheil M, Fischer C, Rappold G: Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients. Clin Rheumatol 2004;23:338–344.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.